Innovative Device Detects Recurrent Atrial Fibrillation

Recurrent atrial fibrillation (AF) can be detected accurately and in a timely fashion in patients who use the CardioBip device for daily monitoring, following catheter ablation procedures.

The CardioBip hand held device offers a solution to the problem of urgent electrocardiogram (ECG) telemonitoring, and provides a comprehensive and accurate source for wireless ECG data transmission. The device employs only three integrated electrodes, and recordings are made by holding the instrument against the patient's chest, similar to single lead devices. The absence of any cables and the integrated nature of its electrodes harbor the potential for integration with popular hand held personal digital assistant (PDA) platforms.


The data collected by CardioBip provides sufficient information to allow an accurate, immediate reconstruction of a complete 12-lead ECG from a calibrated, patient-specific transformation matrix. The data may also be analyzed with the Cardio3KG array of three dimensional (3D) analytical tools, a proprietary set of algorithms and tools that generate a representation of cardiac electrical activity as a function of time, superimposing the diagnostically relevant electrical information on an intuitive, revolving 3D anatomic model of the heart; the model represents a "virtual sphere" of normalized electrical activity, ensuring accurate and balanced representation of all heart regions. The CardioBip device and the Cardio3KG software are products of NewCardio (Santa Clara, CA, USA).

"CardioBip is an effective, accurate, and patient-friendly solution for long-term monitoring of cardiac conditions,” said Dorin Panescu, PhD, NewCardio's Chief Technical Officer (CTO). "Study data show that CardioBip has the potential to contribute to clinical management of patients affected by atrial fibrillation.”

AF is a serious medical condition that doubles mortality risk and increases risk of stroke five-fold. AF affects an estimated 1% of the worldwide population, with nearly three million AF patients in the United States and six million AF patients in Europe; patients often need ambulatory monitoring to detect AF recurrences. Currently available AF monitoring devices have significant limitations, such as relatively few monitoring leads and the need to wear a Holter device with attached wires and skin electrodes.

Related Links:

NewCardio